bioihbjkbjnl/mcl2 huggingface dataset:
Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females
Condition: Ureteral Stent Occlusion; Exposure Laser; Ureterostomy; Functional Disturbance; Vaginal Diseases; Injury of Bladder; Excessive Repair; Calculi
MeSH terms: Vaginal Diseases; Calculi
Intervention: Desflurane; Sevoflurane
Intervention MeSH terms: Sevoflurane; Desflurane
Phase: Phase 4
Study type: Interventional
Primary purpose: Supportive Care
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 57.0
Sex: Female
Minimum age: 60 Years
Maximum age: 85 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Sevoflurane; Desflurane

Summary:

      Numerous studies demonstrate that patients have improved immediate recovery characteristics
      following desflurane anesthesia compared to other volatile agents, including sevoflurane.
      There is limited evidence in the literature to suggest that patients undergoing sevoflurane,
      compared to desflurane anesthesia, may suffer from limitation in function and cognitive
      ability for an undetermined, but prolonged period of time following surgery. These
      differences are not explained pharmacokinetically and may be a result of a direct neurotoxic
      effect of sevoflurane. An unresolved question is the time required for the ability to return
      to complex tasks, such as driving, following anesthesia. Commonly, patients are advised not
      to drive or make important decisions for 24 hours following anesthesia, but this is not
      well-studied and proscribed on an empiric, rather than scientific, basis with very limited
      data available.This study will better define recovery characteristics and characterize the
      severity and duration of cognitive impairment following sevoflurane or desflurane anesthesia
      after brief outpatient urologic surgery in elderly females using tests of cognitive ability
      coupled with performance on a driving simulator and cognitive task tests to objectively
      measure not only testing performance, but also cognitive effort in performing these tests.
    

Eligibility criteria:

        Inclusion Criteria:

          -  > 65 years old, female subjects

          -  Scheduled for brief urologic surgery (Cyctoscopy, Ureteral stent, Laserlithotripsy,
             Ureteroscopy, Vaginal sling, Bladder injury repair, Rectocele repair and Stone
             extraction)

          -  Ability to read, write and speak English language

          -  Driving at least one year

        Exclusion Criteria:

          -  Preexisting neurological impairment in thinking process

          -  Renal insufficiency or failure

          -  Lack of command of English language

          -  Inability to drive

          -  Motion Sickness
Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color
Condition: Nasolabial Folds
Intervention: Radiesse® Injectable Dermal Filler
Intervention description: Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 100.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Moderate to severe wrinkles and folds such as nasolabial folds

Summary:

      Post marketing study to assess the likelihood of hypertropic scarring, keloid formation and
      hyper- or hypopigmentation in patients with Fitzpatrick Skin Types IV, V, and VI receiving
      nasolabial fold treatment with Radiesse® Injectable Dermal Filler
    

Eligibility criteria:

        Inclusion Criteria:

          -  Is at least 18 years of age.

          -  Has Fitzpatrick Skin Type IV, V, or VI.

          -  Understands and accepts the obligation not to receive any other procedures or
             treatments in the nasolabial fold for 6 months.

        Exclusion Criteria:

          -  Has history of hyper- or hypo-pigmentation in the nasolabial folds, keloid formation,
             or hypertrophic scarring.

          -  Has a known bleeding disorder or is receiving drug therapy that could increase the
             risk of bleeding.

          -  Has nasolabial folds that are too severe to be corrected in one treatment session.

          -  Has received any dermal filler or other injections, grafting or surgery in either
             nasolabial fold.

          -  Is pregnant, lactating, or not using acceptable contraception.
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
Condition: Polycystic Kidney, Autosomal Dominant
MeSH terms: Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant
Intervention: Curcumin; Placebo
Intervention description: Dietary Supplement
Intervention MeSH terms: Curcumin
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 68.0
Sex: All
Minimum age: 6 Years
Maximum age: 25 Years
Healthy volunteers: No

Summary:

      The proposed research will determine the effectiveness of curcumin for improving the health
      and function of arteries in children and young adults with autosomal dominant polycystic
      kidney disease (ADPKD). The study also will provide insight into how curcumin improves artery
      health by determining the physiological mechanisms (biological reasons) involved and offer
      exploratory evidence if curcumin can slow kidney growth. This will be done by comparing these
      measurements in children and young adults who are randomized to receive either curcumin or
      placebo for 1 year.
    

Eligibility criteria:

        Inclusion Criteria:

          -  ADPKD diagnosis

          -  Normal renal function (estimated glomerular filtration rate >80 mL/min/1.73m^2)

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Currently taking a curcumin supplement

          -  Current smoking or history of smoking in the past 12 months

          -  Marijuana use within 2 weeks prior to FMDBA and aPWV testing

          -  Antioxidantand/or omega-3 fatty acid use within the past 4 weeks prior to FMDBA and
             aPWV testing and for the duration of the study

          -  Alcohol dependence and abuse

          -  History of hospitalization within the last 3 months

          -  Active infection or antibiotic therapy

          -  Pregnancy, lactation, or unwillingness to use adequate birth control

          -  Body-mass index >95th percentile in ages 6-17 or >40 kg/m2 in ages 18-25

          -  Inability to cooperate with/clinical contraindication for MRI including severe
             claustrophobia, implants, devices, or non-removable body piercings
Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis
Condition: Atopic Dermatitis
MeSH terms: Dermatitis, Atopic; Dermatitis; Eczema
Intervention: Atopiclair Nonsteroidal Cream; Aquaphor Healing Ointment; EpiCeram
Intervention MeSH terms: Decanoic acid; Petrolatum
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Investigator)
Enrollment: 39.0
Sex: All
Minimum age: 2 Years
Maximum age: 17 Years
Healthy volunteers: No
Keywords: Atopic Dermatitis; Wake Forest; Dermatology; Skin; Over-the-counter; Moisturizer; Children

Summary:

      The purpose of this study is to compare the efficacy and cost effectiveness of Aquaphor
      Healing Ointment, Atopiclair and EpiCeram as a monotherapy in mild to moderate AD.

      The investigators hypothesize that no statistical difference will exist in the efficacy
      between an over-the-counter moisturizer, Aquaphor Healing Ointment, compared to prescription
      devices Atopiclair and EpiCeram in treating mild to moderate AD. Therefore, Aquaphor will be
      most cost-effective than Atopiclair or EpiCeram.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male or female with mild to moderate atopic dermatitis, 2-17 years of age, that agree
             to participate and provide written consent (and assent if applicable)

          -  Have an investigator Global Assessment of mild to moderate atopic dermatitis (IGA
             rating of 2-3 in the Investigator Global Assessment)

          -  Percentage of overall body surface area of involvement (BSA) must be > 1% and may
             include facial and intertriginous skin.

        Exclusion Criteria:

          -  Use within 4 weeks of baseline of systemic anti-inflammatory medication, which may
             influence study outcome, such as systemic corticosteroids.

          -  Application or use within 2 weeks of baseline of topical corticosteroid medications or
             topical anti-inflammatory medication, which may influence study outcome.

          -  Presence of a concurrent medical condition, which is determined by the investigator to
             potentially interfere with study outcomes or patient assessments.

          -  Introduction of any other prescription medication, topical or systemic, for atopic
             dermatitis while participating int he study (oral antihistamines will be allowed, so
             long as they are neither initiated nor discontinued during the course of this study)

          -  Amount of disease involvement that would require >60gm of cream in a 1 week period

          -  Subjects with known allergy or sensitivity to Aquaphor Healing Ointment, Atopiclair or
             EpiCeram or components therein.
Neuroimaging of Anesthetic Modulation of Human Consciousness
Condition: Healthy
Intervention: Propofol
Intervention description: Propofol administration
Intervention MeSH terms: Propofol
Phase: Phase 4
Study type: Interventional
Primary purpose: Basic Science
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 30.0
Sex: All
Minimum age: 18 Years
Maximum age: 40 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This study's purpose is to see if mental functions take place during different levels of
      anesthesia, using a commonly used drug (Propofol). fMRI (functional Magnetic Resonance
      Imaging, or "brain imaging") shows areas in the brain involved in thinking at different
      depths of anesthesia.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Must have a body mass index (BMI) less than 30.

          2. Must be right handed

          3. Must be English speaking

          4. Must be capable of giving written informed consent.

          5. Must have history of playing tennis (or any type of racquet sport) at least 30 times
             over lifetime.

        Exclusion Criteria:

          1. History of obstructive sleep apnea;

          2. History of a difficult airway with a previous anesthetic;

          3. History of neurological disorders;

          4. Hypertension or other cardiovascular abnormalities;

          5. Pulmonary hypertension or other pulmonary abnormalities;

          6. Gastroesophageal reflux disease (GERD) or heartburn;

          7. History of significant head injury with loss of consciousness;

          8. Learning disability or other developmental disorder;

          9. Allergic reactions to eggs;

         10. Pregnant or nursing mothers;

         11. Contraindications to neuroimaging methods;

         12. Inability or unwilling to fast, or withhold food and liquid intake, for 8 hours prior
             to your scheduled study visit.

         13. Unwilling to abstain from alcohol use for 24 hours prior to your scheduled study
             visit.

         14. History of drug use, or have a positive drug screen.

         15. Tattoos on the head or neck region - all other tattoos are subject to determination by
             investigators.

         16. Any impairment, activity or situation that in the judgment of the study coordinator or
             Principal Investigators would prevent satisfactory completion of the study protocol.
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Condition: COPD; Chronic Bronchitis; Emphysema
MeSH terms: Bronchitis; Bronchitis, Chronic; Emphysema
Intervention: pneumatic vest; placebo pneumatic vest
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Enrollment: 50.0
Sex: All
Minimum age: 45 Years
Maximum age: 85 Years
Healthy volunteers: No
Keywords: COPD

Summary:

      The purpose of this study is to show that one form of mechanical airway clearance techniques,
      High Frequency Chest Wall Oscillation (HFCWO)using a pneumatic vest, will diminish
      exacerbations of COPD which will improve respiratory health status.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Physician Diagnosis of COPD,chronic bronchitis and/or emphysema

          -  Forced Expiratory Volume in 1 second (FEV1)/ Forced Vital Capacity (FVC) < or = 70%

          -  FEV1 < or = 65%

          -  Current or former smoker > or = 20 pack years

          -  History of 1 or more COPD exacerbations in past 6 months necessitation
             hospitalization, Emergency Department (ED) visit, antibiotic or steroid prescription

        Exclusion Criteria:

          -  Other lung diseases

          -  Co-morbid illnesses such as cancer, liver disease, cardiomyopathy

          -  Recent chest wall or abdominal trauma or surgery that would preclude using the vest
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
Condition: Anemia
MeSH terms: Anemia
Intervention: Peginesatide; Epoetin alfa
Intervention description: All participants will receive peginesatide for the first 24 weeks.; All participants converted to epoetin alfa at week 25 for a total of 32 weeks
Intervention MeSH terms: Epoetin Alfa
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 41.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Anemia, Chronic Kidney Disease, End Stage Renal Disease, erythropoiesis-stimulating agents, Hemodialysis, Hemoglobin

Summary:

      The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can be
      converted to epoetin alfa by using a predefined conversion table while achieving a stable
      hemoglobin.
    

Eligibility criteria:

        Key Inclusion Criteria:

          -  Receiving hemodialysis 3 times a week

          -  Receiving epoetin alfa IV 3 times a week

          -  Hemoglobin concentration ≥ 9.0 and ≤ 12.0 g/dL within 8 weeks of or during screening

        Key Exclusion Criteria:

          -  Systemic hematologic disease

          -  Changes in Epoetin alfa dose by ≥ 50% within 8 weeks of or during screening
Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance
Condition: Expectancy Versus Pharmacotherapy Effect of Adderall
Intervention: Adderall; Placebo
Intervention description: Participants will be administered Adderall; Participants will be administered placebo
Intervention MeSH terms: Adderall
Phase: Phase 4
Study type: Interventional
Primary purpose: Health Services Research
Allocation: Randomized
Intervention model: Factorial Assignment
Intervention model description: 2 X 2, within-subjects, balanced placebo design
Masking: Double (Participant, Investigator)
Masking description: This will be a double-blind study. Research assistants will administer capsules, and based on package labeling, tell the participant if they are being administered Adderall or placebo. However, researchers and participants will be blind to which medication is actually being administered.
Enrollment: 4.0
Sex: All
Minimum age: 18 Years
Maximum age: 24 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The purpose of this balanced-placebo design study is to pilot a larger study to further
      explore the current evidence that stimulant medications are not cognitive enhancers, despite
      this rampant belief in young adults. While the lack of cognitive enhancement from stimulant
      medication has been documented in prior research, this study is the first to utilize
      neuroimaging technology to examine brain regions activated during neurocognitive tasks when
      participants believe they have been administered stimulant medication or placebo.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age (18-24)

          -  College student with at least average IQ

          -  Willingness to standardize caffeine intake to 100 mg on day of study

        Exclusion Criteria:

          -  Attention Deficit/Hyperactivity Disorder (ADHD)

          -  First degree relative with ADHD

          -  Unwillingness to comply with caffeine specifications

          -  Regular use of Adderall

          -  Pregnant/breastfeeding

          -  History of substance use disorders

          -  Illicit stimulant use within the last year

          -  Contraindications to stimulants (i.e., tics, Tourette's, cardiac disease,
             hypertension)

          -  Uncontrolled medical illness

          -  Active contagious infection
Treatment of Giardia Lamblia Infections in Children
Condition: GIARDIASIS
MeSH terms: Giardiasis
Intervention: Metronidazole; Tinidazole
Intervention description: P/r suppositories; P/o tablets
Intervention MeSH terms: Metronidazole; Tinidazole
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 8.0
Sex: All
Minimum age: 6 Months
Maximum age: 10 Years
Healthy volunteers: No

Summary:

      This study investigates the efficacy and safety of rectally administered metronidazole for
      pediatric Giardia lamblia infection, as well as the acceptance of this treatment regimen by
      patients/caregivers. The investigators hypothesize that rectal metronidazole is non-inferior
      to single-dose of oral tinidazole and will cure at least 72% of patients, a well as will be
      tolerated as good as tinidazole.
    

Eligibility criteria:

        Inclusion Criteria:

          -  clinical symptoms could be explained by giardiasis AND

          -  fecal samples will test positive for the presence of G.lamblia in Uusimaa laboratory
             (HUSLAB)

        Exclusion Criteria:

          -  age <6 mo or >10 years

          -  weight <9.5 kg

          -  the absence of symptoms

          -  co-infection with another pathogen, which may cause giardiasis-like symptoms
Treatment of Smoking Lapses and Relapses
Condition: Smoking Cessation
MeSH terms: Recurrence
Intervention: nicotine patch, experimental use; nicotine patch, labeled use
Intervention description: nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.; nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
Intervention MeSH terms: Nicotine
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 701.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: nicotine dependence; smoking cessation; lapse; relapse; tobacco; nicotine patch; nicotine replacement therapy; NRT

Summary:

      Many smokers who try to stop smoking with nicotine medications (NM) such as gum, lozenge and
      patch, go back to smoking (i.e., a slip or lapse). Currently, labeling on many NM products
      tells smokers who lapse while using NM to stop NM. However, some studies suggest it is safe
      to continue NM upon a lapse and that doing so dramatically increases success at quitting. The
      investigators will test this by doing a randomized trial in which all treatment and measures
      are done from home with paper, phone or computer surveys. The investigators will recruit
      smokers who want to quit, provide them with 10 weeks of nicotine patch treatment and 5 weeks
      of counseling. One group will be asked to stop use of the patch if they lapse and the other
      group will be asked to continue use of the patch if they lapse. The investigators will
      compare the groups on their success at quitting and side-effects.
    

Eligibility criteria:

        Inclusion Criteria:

          -  at least 18 years old

          -  daily smoker of 10 or more cigarettes per day for at least 1 year

          -  state they plan to probably or definitely quit smoking in the next month

          -  have a home or cell phone

          -  willing to use nicotine patch

          -  good command of written and spoken English

          -  weigh at least 100 pounds

          -  US citizen or permanent resident alien

        Exclusion Criteria:

          -  use of non-cigarette tobacco in the last month

          -  use of a smoking cessation medication or smoking cessation counseling in the last
             month

          -  medical contraindication to use of patch

          -  other person in household already in our study

          -  previously a participant in the study

          -  currently pregnant or breast feeding

          -  plan to become pregnant in the next 6 months

          -  regularly works the overnight shift

          -  use of electronic cigarettes in the last month